<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01009957</url>
  </required_header>
  <id_info>
    <org_study_id>PolEver</org_study_id>
    <nct_id>NCT01009957</nct_id>
  </id_info>
  <brief_title>Everolimus on CKD Progression in ADPKD Patients</brief_title>
  <official_title>Everolimus on CKD (Chronic Kidney Disease) Progression in ADPKD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A. Manzoni Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A. Manzoni Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down
      the progression of CKD in ADPKD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Considering the inhibitor activity of Everolimus on mTOR, our hypothesis is to evaluate its
      possible utility on the progression of CKD in ADPKD patients by reducing the rate of increase
      of renal cysts.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After primary completition date, experimental drug was no longer available
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of GFR (according to MDRD formula) during a two-year follow up</measure>
    <time_frame>Two year-followup</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of creatinine clearance and GFR (according to Cockcroft-Gault formula) during a two-year follow up</measure>
    <time_frame>Two year-followup</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in kidney size and renal and liver cysts dimensions evaluated by NMR at basal and at the end of the study</measure>
    <time_frame>Two year-followup</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile of everolimus (leucopenia, thrombocytopenia, lipid profile and other adverse events</measure>
    <time_frame>Two year-followup</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of phosphatemia, phosphaturia and urinary cytokines on primary end point</measure>
    <time_frame>Two year-followup</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Polycystic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus + standard therapy for CKD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy for CKD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>0.75 mg x 2 / day</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>mTOR inhibitors</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects over 18 years of both genders

          2. Clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD)

          3. GFR, according to MDRD formula, between 30 and 90 ml/min/1.73 mq

          4. Previous follow up of two years, with a creatinine evaluation at least once a year

          5. GFR reduction of at least 2.5 ml/min/year (according to MDRD formula)

        Exclusion Criteria:

          1. Pregnancy, lactating, males and females without adequate contraception

          2. Leucopenia (&lt; 3,000 leucocytes/mm3) or thrombocytopenia (&lt; 100,000 platelets/mm3)

          3. Dyslipidemia (cholesterol or triglycerides &gt; 260 mg/dl with treatment)

          4. Urinary tract infection

          5. Patients who cannot undergoing NMR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Locatelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology and Dialysis Department - A. Manzoni Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. Spedali Civili Di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alessandro Manzoni Hospital, Nephrology and Dialysis Department</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modena Hospital</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Patologia Sistematica - Università Federico 2°</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Guglielmo da Saliceto&quot; - Nephrology and Dialysis Department</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.M.I.D. - Presidi Ospedalieri ASL 4</name>
      <address>
        <city>Torino</city>
        <zip>10152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile San Bortolo Vicenza</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2009</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A. Manzoni Hospital</investigator_affiliation>
    <investigator_full_name>Prof. Francesco Locatelli</investigator_full_name>
    <investigator_title>Prof. Francesco Locatelli</investigator_title>
  </responsible_party>
  <keyword>ADPKD</keyword>
  <keyword>CKD</keyword>
  <keyword>Renal disease progression</keyword>
  <keyword>Everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

